×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADAP – adaptimmune therapeutics plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADAP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/5
09:31 am
adap
Adaptimmune to Participate in Scientific and Medical Conferences this November and December [Yahoo! Finance]
Medium
Report
Adaptimmune to Participate in Scientific and Medical Conferences this November and December [Yahoo! Finance]
10/10
02:44 pm
adap
OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR [Yahoo! Finance]
Low
Report
OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR [Yahoo! Finance]
10/1
08:00 am
adap
Immuno-Oncology 360º Announces 2025 Keynotes and Featured Speakers for the 11th Annual Meeting in Boston
Low
Report
Immuno-Oncology 360º Announces 2025 Keynotes and Featured Speakers for the 11th Annual Meeting in Boston
10/1
07:30 am
adap
ReCode Announces Two Key Additions to Scientific Advisory Board
Low
Report
ReCode Announces Two Key Additions to Scientific Advisory Board
9/25
06:51 am
adap
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions [Yahoo! Finance]
Medium
Report
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions [Yahoo! Finance]
8/29
09:51 am
adap
Unlock the Full Potential of Cell and Gene Therapies: The 2024 GenScript Biotech Global Forum Heads to London
Neutral
Report
Unlock the Full Potential of Cell and Gene Therapies: The 2024 GenScript Biotech Global Forum Heads to London
8/15
08:14 am
adap
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago [Yahoo! Finance]
Medium
Report
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago [Yahoo! Finance]
8/14
02:59 pm
adap
Medigene AG (MDGEF) Q2 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Medigene AG (MDGEF) Q2 2024 Earnings Call Transcript [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/1
05:01 pm
adap
Form 8-K Adaptimmune Therapeutics For: Nov 01
Medium
Report
Form 8-K Adaptimmune Therapeutics For: Nov 01
9/23
04:16 pm
adap
Form 8-K Adaptimmune Therapeutics For: Sep 23
Medium
Report
Form 8-K Adaptimmune Therapeutics For: Sep 23
8/12
07:24 am
adap
Form 10-Q Adaptimmune Therapeutics For: Jun 30
Medium
Report
Form 10-Q Adaptimmune Therapeutics For: Jun 30
8/12
07:06 am
adap
Form 8-K Adaptimmune Therapeutics For: Aug 12
Low
Report
Form 8-K Adaptimmune Therapeutics For: Aug 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/13
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
200.0%
11/28 Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool 23.2%
11/2 Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds [Yahoo! Finance News] 14.6%
4/29 Form 8-K Adaptimmune Therapeutics For: Apr 29 12.6%
7/3 Form 4 Adaptimmune Therapeutics For: Jul 02 Filed by: Zaks Tal Zvi 12.1%
4/1 Form 3 Adaptimmune Therapeutics For: Apr 01 Filed by: Wood Gavin 12.1%
7/22 Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center 11.6%
4/13 2 Penny Stocks That Could Make You Rich [The Motley Fool] 10.1%
6/10 Cancer Immunotherapy Markets, 2023 - ResearchAndMarkets.com 9.7%
9/9 United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 9.7%
11/28 Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool 23.2%
11/2 Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds [Yahoo! Finance News] 14.6%
4/29 Form 8-K Adaptimmune Therapeutics For: Apr 29 12.6%
7/3 Form 4 Adaptimmune Therapeutics For: Jul 02 Filed by: Zaks Tal Zvi 12.1%
4/1 Form 3 Adaptimmune Therapeutics For: Apr 01 Filed by: Wood Gavin 12.1%
7/22 Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center 11.6%
4/13 2 Penny Stocks That Could Make You Rich [The Motley Fool] 10.1%
6/10 Cancer Immunotherapy Markets, 2023 - ResearchAndMarkets.com 9.7%
9/9 United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 9.7%
TOP News Decliners
8/5
Form 3 Adaptimmune Therapeutics For: Aug 01 Filed by: Lunger John
-19.0%
11/6 Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update -18.6%
1/14 Form 8-K Adaptimmune Therapeutics For: Jan 13 -18.4%
5/6 Form 8-K Adaptimmune Therapeutics For: May 06 -15.1%
4/27 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) had its price target lowered by analysts at Citigroup Inc from $8.00 to $5.00. They now have a "buy" rating on the stock. -15.0%
8/1 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -14.9%
9/11 Form EFFECT Adaptimmune Therapeutics -13.4%
4/29 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -12.3%
8/1 The T-cell Immunotherapies Market is Projected to Reach USD 26 Billion by 2030, Growing at an Annualized Rate of 41.5%, Claims Roots Analysis -11.1%
6/5 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%
11/6 Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update -18.6%
1/14 Form 8-K Adaptimmune Therapeutics For: Jan 13 -18.4%
5/6 Form 8-K Adaptimmune Therapeutics For: May 06 -15.1%
4/27 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) had its price target lowered by analysts at Citigroup Inc from $8.00 to $5.00. They now have a "buy" rating on the stock. -15.0%
8/1 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -14.9%
9/11 Form EFFECT Adaptimmune Therapeutics -13.4%
4/29 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -12.3%
8/1 The T-cell Immunotherapies Market is Projected to Reach USD 26 Billion by 2030, Growing at an Annualized Rate of 41.5%, Claims Roots Analysis -11.1%
6/5 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: